Q-omics provides the consensus-scored ZNF705B profile across patient tissues and cancer cell-line models. ZNF705B expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF705B is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, ZNF705B RNA expression shows 7,589 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KIRC, and TGCT as cancer lineages where ZNF705B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF705B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF705B survival associations across molecular data types. ZNF705B RNA expression shows survival associations in the most cancer types (5), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF705B RNA expression–survival associations across cancer types. High ZNF705B expression shows unfavorable associations in UCS, STAD, UCEC, LUSC and OV. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF705B RNA expression.
This table summarizes ZNF705B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF705B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF705B shows higher tumor expression in KIRC. The KIRC box plot shows higher ZNF705B RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .038).
This table shows molecular features associated with ZNF705B in patient tissues and cancer cell lines. In patient samples, ZNF705B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF705B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
